Vernalis PLC Regulatory News (VER)

20 Sep 2006 12:09

Vernalis PLC20 September 2006 20 September 2006 Vernalis plc to Present at UBS Global Life Sciences Conference on September 26, 2006 WINNERSH, U.K., September 20, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), aspecialty bio-pharmaceutical and drug development company, today announced thatSimon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer,will participate in the UBS Global Life Sciences Conference to be held September25-28, 2006 at the Grand Hyatt in New York City. Mr. Sturge is scheduled topresent an overview of the Company's business activities and product pipeline at8:00 AM Eastern time on Tuesday, September 26, 2006. To listen to the audio webcast of the presentation, please visit:www.ibb.ubs.com About VernalisVernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Lazar Partners LtdGregory Gin 212-867-1762 Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products and includingthat of Frova(R) for menstrual migraine, the Company's ability to find partnersfor the development and commercialisation of its products, the benefits ofre-acquiring Frova(R) in North America and the partnership with Endo on theCompany's liquidity and results of operations, as well as the Company's futurecapital raising activities. Forward-looking statements involve risks anduncertainties. Actual events could differ materially from those projected hereinand depend on a number of factors including the success of the Company'sresearch strategies, the applicability of the discoveries made therein, thesuccessful and timely completion of clinical studies, including with respect toFrova(R) and the Company's other products, the uncertainties related to theregulatory process, the ability of the Company to identify and agree beneficialterms with suitable partners for the commercialisation and/or development ofFrova(R) and other products, as well as the achievement of expected synergiesfrom such transactions, the acceptance of Frova(R) and other products byconsumers and medical professionals, the successful integration of completedmergers and acquisitions and achievement of expected synergies from suchtransactions, and the ability of the Company to identify and consummate suitablestrategic and business combination transactions. This information is provided by RNS The company news service from the London Stock Exchange